CD34 and angina pectoris: In support of this approach, a meta-analysis of three clinical trials conducted between 2007 and 2016 demonstrated that intramyocardial injection of autologous CD34+ adult stem cells improved exercise capacity, reduced angina frequency, and reduced mortality in RA patients [4].